RxDoctor Payments Data

Veshana Ramiah, MD

Hematology & Oncology · Raleigh, NCNPI 1043377591

Payments from drug & device makers

$1,407in general payments, 2019–2025

Across 75 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$270
  • Johnson & Johnson$153
  • Pfizer$131
  • AstraZeneca$124
  • Bristol Myers Squibb$77
  • Daiichi Sankyo Inc.$57
  • plus $595 from 24 others

What the payments were for

  • Food & beverage$1,36497%
  • Education$433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,407 in reported general payments places this provider in the 30th percentile of 358 hematology & oncology providers in North Carolina.

See all hematology & oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,578
Medicare patients
239
Services billed
497

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide26$361,507
NubeqaDarolutamide27$352,138
Abiraterone Acetate20$23,997
EliquisApixaban25$19,850
ValacyclovirValacyclovir Hcl38$1,827
Ondansetron OdtOndansetron51$1,187
Dexamethasone57$1,120
Prochlorperazine Maleate47$940
Bicalutamide14$194
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$106
Prednisone24$97

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$36$361,50726 claims
BayerNubeqa$21$352,13827 claims
PfizerEliquis$131$19,85025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 358 hematology & oncology providers in North Carolina.

Other hematology & oncology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →